Cargando…

Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer

Intravenous (IV) atezolizumab is approved for non–small cell lung and other cancers. Subcutaneous (SC) atezolizumab coformulated with recombinant human hyaluronidase, a permeation enhancer for SC dispersion and absorption, is being developed to improve treatment options, reduce burden, and increase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Felip, Enriqueta, Burotto, Mauricio, Zvirbule, Zanete, Herraez‐Baranda, Luis A., Chanu, Pascal, Kshirsagar, Smita, Maiya, Vidya, Chan, Phyllis, Pozzi, Emanuela, Marchand, Mathilde, Monchalin, Marion, Tanaka, Kunihiko, Tosti, Nadia, Wang, Bei, Restuccia, Eleonora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518371/ https://www.ncbi.nlm.nih.gov/pubmed/33788415 http://dx.doi.org/10.1002/cpdd.936

Ejemplares similares

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study
por: Gligorov, Joseph, et al.
Publicado: (2022)

Baseline risk factors associated with immune related adverse events and atezolizumab
por: Madjar, Katrin, et al.
Publicado: (2023)

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
por: Morrissey, Kari M., et al.
Publicado: (2019)

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
por: Huang, Weize, et al.
Publicado: (2022)

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework
por: Chan, Phyllis, et al.
Publicado: (2021)

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
por: Shemesh, Colby S., et al.
Publicado: (2019)

Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
por: Wu, Benjamin, et al.
Publicado: (2021)

Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union
por: Patel, Hina, et al.
Publicado: (2021)

Novel Coronavirus, Access to Abortion Services, and Bridging Western and Indigenous Knowledges in a Postpandemic World
por: Monchalin, Renée
Publicado: (2021)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
por: Felip, Enriqueta, et al.
Publicado: (2008)

Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer
por: Gridelli, Cesare, et al.
Publicado: (2011)

PI3K Pathway in NSCLC
por: Martinez-Martí, Alex, et al.
Publicado: (2012)

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
por: Nadal, Ernest, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
por: Dienstmann, Rodrigo, et al.
Publicado: (2011)

Two Cases of Atezolizumab-Induced Hypophysitis
por: Kanie, Keitaro, et al.
Publicado: (2017)

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
por: Lambert, Nicolas, et al.
Publicado: (2022)

Bamboo foreign bodies mimicking traumatic subcutaneous emphysema
por: Kudo, Shunsuke, et al.
Publicado: (2020)

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
por: Peters, Solange, et al.
Publicado: (2022)

Collagenous colitis and atezolizumab therapy: an atypical case
por: Gallo, Antonella, et al.
Publicado: (2020)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
por: Nouso, Kazuhiro, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
por: Shemesh, Colby S., et al.
Publicado: (2020)

External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data
por: Kassir, Nastya, et al.
Publicado: (2023)

Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors
por: Riveiro-Barciela, Mar, et al.
Publicado: (2023)

Symptoms and Experiences with Small Cell Lung Cancer: A Mixed Methods Study of Patients and Caregivers
por: Bebb, D. Gwyn, et al.
Publicado: (2023)

Non-contact photoacoustic tomography and ultrasonography for tissue imaging
por: Rousseau, Guy, et al.
Publicado: (2011)

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)
por: Peters, Solange, et al.
Publicado: (2021)

A Rare Case Presentation of Vitiligo Associated With Atezolizumab
por: Nwanwene, Kemnasom, et al.
Publicado: (2023)

Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab
por: Suga, Takayoshi, et al.
Publicado: (2023)

Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes
por: Endo, Yukinori, et al.
Publicado: (2023)

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
por: Zhou, Caicun, et al.
Publicado: (2023)

‘By identifying myself as Métis, I didn’t feel safe…’: Experiences of navigating racism and discrimination among Métis women, Two-Spirit and gender diverse community members in Victoria, Canada
por: Paul, Willow, et al.
Publicado: (2023)

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
por: Moore, Kathleen N., et al.
Publicado: (2021)

Nose to brain delivery of Efavirenz nanosuspension for effective neuro AIDS therapy: in-vitro, in-vivo and pharmacokinetic assessment
por: Kakad, Smita, et al.
Publicado: (2021)

Use of Atezolizumab for Bladder and Non–Small Cell Lung Cancers
por: Moore, Kayla Faith
Publicado: (2017)

A Case Report of Atezolizumab Induced Tumor Lysis Syndrome
por: Fa’ak, Faisal, et al.
Publicado: (2019)

Atezolizumab-induced bilateral anterior uveitis: A case report
por: Mito, Tsuyoshi, et al.
Publicado: (2021)

Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c8c7q8fkctjne8va3u3s7njn4b